To extend the work beyond developmental stages, we showed that podocyte-selective deletion of Vegfa from fully mature glomeruli led to a thrombotic microangiopathy phenotype too, supporting a causal on-target effect of anti-VEGF agents and TMA in susceptible patients (23). The gene discussed is VEGFA; the disease is Genetic thrombotic microangiopathy.